These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

647 related items for PubMed ID: 16740558

  • 1. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials.
    Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C.
    BMJ; 2006 Jun 03; 332(7553):1302-8. PubMed ID: 16740558
    [Abstract] [Full Text] [Related]

  • 2. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.
    Coxib and traditional NSAID Trialists' (CNT) Collaboration, Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, Bombardier C, Cannon C, Farkouh ME, FitzGerald GA, Goss P, Halls H, Hawk E, Hawkey C, Hennekens C, Hochberg M, Holland LE, Kearney PM, Laine L, Lanas A, Lance P, Laupacis A, Oates J, Patrono C, Schnitzer TJ, Solomon S, Tugwell P, Wilson K, Wittes J, Baigent C.
    Lancet; 2013 Aug 31; 382(9894):769-79. PubMed ID: 23726390
    [Abstract] [Full Text] [Related]

  • 3. Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen.
    De Vecchis R, Baldi C, Di Biase G, Ariano C, Cioppa C, Giasi A, Valente L, Cantatrione S.
    Minerva Cardioangiol; 2014 Dec 31; 62(6):437-48. PubMed ID: 25029569
    [Abstract] [Full Text] [Related]

  • 4. Non-steroidal anti-inflammatory drug-induced cardiovascular adverse events: a meta-analysis.
    Gunter BR, Butler KA, Wallace RL, Smith SM, Harirforoosh S.
    J Clin Pharm Ther; 2017 Feb 31; 42(1):27-38. PubMed ID: 28019014
    [Abstract] [Full Text] [Related]

  • 5. NSAIDs and serious cardiovascular disorders: especially cox-2 inhibitors and diclofenac.
    Prescrire Int; 2016 Jan 31; 25(167):14-6. PubMed ID: 26942254
    [Abstract] [Full Text] [Related]

  • 6. Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.
    Matchaba P, Gitton X, Krammer G, Ehrsam E, Sloan VS, Olson M, Mellein B, Hoexter G, Orloff J, Garaud JJ.
    Clin Ther; 2005 Aug 31; 27(8):1196-214. PubMed ID: 16199245
    [Abstract] [Full Text] [Related]

  • 7. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk.
    Moore RA, Derry S, McQuay HJ.
    BMC Musculoskelet Disord; 2007 Aug 03; 8():73. PubMed ID: 17683540
    [Abstract] [Full Text] [Related]

  • 8. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review.
    Hooper L, Brown TJ, Elliott R, Payne K, Roberts C, Symmons D.
    BMJ; 2004 Oct 23; 329(7472):948. PubMed ID: 15475342
    [Abstract] [Full Text] [Related]

  • 9. Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective Inhibitor etoricoxib.
    Curtis SP, Ko AT, Bolognese JA, Cavanaugh PF, Reicin AS.
    Curr Med Res Opin; 2006 Dec 23; 22(12):2365-74. PubMed ID: 17265571
    [Abstract] [Full Text] [Related]

  • 10. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
    Weir MR, Sperling RS, Reicin A, Gertz BJ.
    Am Heart J; 2003 Oct 23; 146(4):591-604. PubMed ID: 14564311
    [Abstract] [Full Text] [Related]

  • 11. Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis.
    Latimer N, Lord J, Grant RL, O'Mahony R, Dickson J, Conaghan PG, National Institute for Health and Clinical Excellence Osteoarthritis Guideline Development Group.
    BMJ; 2009 Jul 14; 339():b2538. PubMed ID: 19602530
    [Abstract] [Full Text] [Related]

  • 12. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial.
    Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Matchaba P, Gimona A, Hawkey CJ, TARGET Study Group.
    Lancet; 2009 Jul 14; 364(9435):665-74. PubMed ID: 15325831
    [Abstract] [Full Text] [Related]

  • 13. [Selective COX-2 inhibitor versus nonselective COX-1 and COX-2 inhibitor in the prevention of heterotopic ossification after total hip arthroplasty: a meta-analysis of randomised trials].
    Xu BG, Xue DT, Wang XH, Yan SG.
    Zhongguo Gu Shang; 2014 Jul 14; 27(7):609-14. PubMed ID: 25338452
    [Abstract] [Full Text] [Related]

  • 14. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.
    Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ, Burmester GR, Mysler E, Hochberg MC, Doherty M, Ehrsam E, Gitton X, Krammer G, Mellein B, Gimona A, Matchaba P, Hawkey CJ, Chesebro JH, TARGET Study Group.
    Lancet; 2014 Jul 14; 364(9435):675-84. PubMed ID: 15325832
    [Abstract] [Full Text] [Related]

  • 15. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.
    Chan FK, Lanas A, Scheiman J, Berger MF, Nguyen H, Goldstein JL.
    Lancet; 2010 Jul 17; 376(9736):173-9. PubMed ID: 20638563
    [Abstract] [Full Text] [Related]

  • 16. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
    Cannon CP, Curtis SP, FitzGerald GA, Krum H, Kaur A, Bolognese JA, Reicin AS, Bombardier C, Weinblatt ME, van der Heijde D, Erdmann E, Laine L, MEDAL Steering Committee.
    Lancet; 2006 Nov 18; 368(9549):1771-81. PubMed ID: 17113426
    [Abstract] [Full Text] [Related]

  • 17. The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.
    Hunt RH, Harper S, Watson DJ, Yu C, Quan H, Lee M, Evans JK, Oxenius B.
    Am J Gastroenterol; 2003 Aug 18; 98(8):1725-33. PubMed ID: 12907325
    [Abstract] [Full Text] [Related]

  • 18. Risk of myocardial infarction associated with selective COX-2 inhibitors: meta-analysis of randomised controlled trials.
    Chen LC, Ashcroft DM.
    Pharmacoepidemiol Drug Saf; 2007 Jul 18; 16(7):762-72. PubMed ID: 17457957
    [Abstract] [Full Text] [Related]

  • 19. Aspirin, steroidal and non-steroidal anti-inflammatory drugs for the treatment of Alzheimer's disease.
    Jaturapatporn D, Isaac MG, McCleery J, Tabet N.
    Cochrane Database Syst Rev; 2012 Feb 15; 2012(2):CD006378. PubMed ID: 22336816
    [Abstract] [Full Text] [Related]

  • 20. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
    Huang WF, Hsiao FY, Wen YW, Tsai YW.
    Clin Ther; 2006 Nov 15; 28(11):1827-36. PubMed ID: 17213003
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.